My Watchlist

Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

4

Keryx: This Biotech Is No Zombie

By | More Articles
January 28, 2013 | Comments (1)

Veteran biotech investors see more than their fair share of zombies. Not the flesh-eating kind popularized on the shows like The Walking Dead, but former highflying stocks banished to obscurity after a big drug failure only to rise again without valid reason. But every once in a while, you see a company come back stronger than before it was sent into the penny-stock wilderness.

In this video, Motley Fool health-care analyst discusses how Keryx Pharmaceuticals' impressive 76% pop and how key drug Zerenex's successful trial has reinvented Keryx into more than just a zombie biotech.

The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." Grab a free copy for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

 

 

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Add your comment.

Compare Brokers

Fool Disclosure

DocumentId: 2220388, ~/Articles/ArticleHandler.aspx, 5/25/2013 9:36:24 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 12 hours ago Sponsored by:
DOW 15,303.10 8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
NASD 3,459.14 -0.28 -0.01%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/24/2013 4:00 PM
KERX $8.03 Down +0.00 +0.00%
Keryx Biopharmaceu… CAPS Rating: *
AMGN $105.91 Up +0.29 +0.27%
Amgen, Inc. CAPS Rating: ****
SNY $54.86 Up +0.30 +0.55%
Sanofi (ADR) CAPS Rating: ****
AEZS $2.02 Down -0.01 -0.49%
Aeterna Zentaris,… CAPS Rating: *****
AFFY $1.39 Down -0.01 -0.71%
Affymax, Inc. CAPS Rating: *

Advertisement